Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This first-in-human, multicenter study to evaluate the administration of placebo or AMG 811 single subcutaneous and intravenous dose to subjects with SLE
Phase:
Phase 1
Details
Lead Sponsor:
Amgen